Current status and challenges in prenatal and neonatal screening, diagnosis, and management of congenital heart disease in China

Lancet Child Adolesc Health. 2023 Jul;7(7):479-489. doi: 10.1016/S2352-4642(23)00051-2. Epub 2023 Jun 7.

Abstract

Congenital heart disease (CHD), a wide spectrum of diseases with varied outcomes, is the most common congenital malformation worldwide. In this Series of three papers, we describe the burden of CHD in China; the development of screening, diagnosis, treatment, and follow-up strategies; and challenges associated with the disease. We also propose solutions and recommendations for policies and actions to improve the outcomes of CHD. In the first paper in this Series, we focus on prenatal and neonatal screening, diagnosis, and management of CHD. Based on advanced international knowledge, the Chinese Government has developed a network system comprising prenatal screening, diagnosis of CHD subtypes, specialist consultation appointments, and treatment centres for CHD. A new professional discipline, fetal cardiology, has been formed and rapidly developed. Consequently, the overall coverage of prenatal and neonatal screening and the accuracy of CHD diagnoses have gradually improved, and the neonatal CHD mortality rate has decreased substantially. However, China still faces several challenges in the prevention and treatment of CHD, such as insufficient diagnostic capabilities and unqualified consultation services in some regions and rural areas. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • China / epidemiology
  • Female
  • Heart Defects, Congenital* / diagnosis
  • Heart Defects, Congenital* / therapy
  • Humans
  • Infant, Newborn
  • Neonatal Screening*
  • Pregnancy
  • Prenatal Diagnosis
  • Ultrasonography, Prenatal